SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA. For investors For media +1 858.836.5000 +1 619.510.1281 investorrelations@resmed.com news@resmed.com ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks beyond the tr ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor. Zacks Premium includes access to the Zacks Style Scores as well. What are the Zacks Style ...

Shares of ResMed (RMD) have been strong performers lately, with the stock up 7.1% over the past month. The stock hit a new 52-week high of $260.49 in the previous session. ResMed has gained 48.9% since the start of the year compared to the 5.1% move for the Zacks Medical sector and the 12.8% return for the Zacks Medical - Products industry. What's Driving the Outperformance? The stock has a great record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last fo ...

On Thursday, ResMed Inc RMD reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating the consensus of $1.18 billion, driven by increased demand for sleep devices and masks portfolio and strong growth across the Residential Care Software business. Residential Care Software revenue increased by 12% on a constant currency basis, reflecting continued organic growth in the Residential Care Software portfolio ...

ResMed Inc.’s (RMD) adjusted earnings per share (EPS) in the first quarter of fiscal 2025 were $2.20, up 34.1% year over year. The metric beat the Zacks Consensus Estimate by 8.4%.The adjustments include certain non-recurring expenses/benefits like the amortization of acquired intangibles, along with the income tax effect on those adjustments.GAAP EPS in the reported quarter was $2.11, up 41.6% from the year-ago level.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.Following the annou ...

ResMed Inc. (NYSE:RMD) Q1 2025 Earnings Conference Call October 24, 2024 4:30 PM ET Company Participants Amy Wakeham - Chief Investor Relations Officer Michael Farrell - Chairman and Chief Executive Officer Brett Sandercock - Chief Financial Officer Conference Call Participants Laura Sutcliffe - UBS Craig Wong-Pan - RBC David Low - JPMorgan Saul Hadassin - Barrenjoey Capital Anthony Petrone - Mizuho Daniel Hurren - MST Marquee Mike Matson - Needham & Company Brett Fishbin - KeyBanc Capital Markets Suraj Kal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________________________________________________________________ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.004 per share RMD New York Stock Exchange FORM 10-Q ______________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT ...

For the quarter ended September 2024, ResMed (RMD) reported revenue of $1.22 billion, up 11.1% over the same period last year. EPS came in at $2.20, compared to $1.64 in the year-ago quarter.The reported revenue represents a surprise of +2.98% over the Zacks Consensus Estimate of $1.19 billion. With the consensus EPS estimate being $2.03, the EPS surprise was +8.37%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their ne ...

ResMed (RMD) came out with quarterly earnings of $2.20 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.64 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 8.37%. A quarter ago, it was expected that this maker of medical products for respiratory disorders would post earnings of $2.03 per share when it actually produced earnings of $2.08, delivering a surprise of 2.46%.Over the ...